BiotechTube

Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Poor Thymic Function

Conditions

Poor Thymic Function, Immunodeficiency, Athymia, Immunoreconstitution, Thymus Transplantation, Low T Cell Numbers

Trial Timeline

Aug 1, 2014 → Aug 1, 2023

NCT ID
NCT02274662

About Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus

Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus is a approved stage product being developed by Sumitomo Pharma for Poor Thymic Function. The current trial status is completed. This product is registered under clinical trial identifier NCT02274662. Target conditions include Poor Thymic Function, Immunodeficiency, Athymia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02274662ApprovedCompleted

Competing Products

7 competing products in Poor Thymic Function

See all competitors
ProductCompanyStageHype Score
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
LunestaSumitomo PharmaApproved
85
Rosuvastatin CalciumAstraZenecaPhase 1
33
Lutropin alfa + Follitropin alfaMerckApproved
85
EltrombopagNovartisPhase 2
52
Everolimus (Afinitor®)NovartisPhase 2
52
Cabozantinib S-malateExelixisPhase 2
49

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85